A potential novel therapy for FGFR1‑amplified pancreatic cancer with bone metastasis, screened by next‑generation sequencing and a patient‑derived xenograft model
Open Access
- 28 December 2018
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (2) , 2303-2307
Abstract
Effective therapies are limited for pancreatic cancer, particularly for those with distant tumour metastases. Therefore, more individualised drug screening is urgently required. Next‑generation sequencing (NGS) is a powerful tool to investigate the genomic landscape of patients and the mechanism of drug response, which may provide a broader vision for potential clinical drug screening. Patient‑derived xenograft (PDX) models may have a significant advantage in predicting clinical treatment response. In our previous study, a PDX of pancreatic cancer bone metastasis was established, and NGS was conducted to investigate the molecular information. In the present study, these data were further analysed and fibroblast growth factor receptor 1 (FGFR1) amplification was identified in a panel of 416 cancer‑associated genes. Thus, AZD4547, an inhibitor against FGFR, was selected as a potential therapy, and was evaluated using the PDX model. AZD4547 was shown to exhibit antitumor activity by reducing the expression of FGFR1 and its targets. The present study also demonstrated the high potential of the novel NGS/PDX‑based drug screening platform to improve individualised cancer treatment.Keywords
This publication has 31 references indexed in Scilit:
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase FamilyCancer Research, 2012
- Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial designMolecular Oncology, 2012
- Pancreatic cancerThe Lancet, 2011
- A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced CancerMolecular Cancer Therapeutics, 2011
- The application of next-generation sequencing technologies to drug discovery and developmentDrug Discovery Today, 2011
- Clinical Implications of the Cancer GenomeJournal of Clinical Oncology, 2010
- Pancreatic cancer's initial presentation: back pain due to osteoblastic bone metastasisEuropean Journal of Cancer Care, 2010
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- [Clinical features and management of pancreatic cancer with bone metastases].2004
- Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsBritish Journal of Cancer, 2001